Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 06/24 10:00:03 pm
146.38 USD   -3.87%
06/23 AMGEN : sponsors the QB3@953 life sciences incubator
06/23 AMGEN : Sponsors QB3@953 Incubator For Life Science Startups
06/20 AMGEN : Biotechnology Stocks Under Review - Eleven Biotherapeutics, ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 10:40pm CEST

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on AMGEN, INC.
06/23 AMGEN : sponsors the QB3@953 life sciences incubator
06/23 AMGEN : Sponsors QB3@953 Incubator For Life Science Startups
06/22 AMGEN : Assigned Patent
06/20 AMGEN : Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Gal..
06/20 AMGEN : Esteban Santos appointed Amgen’s vice president, Operations
06/20 Novartis aims to triple biosimilar drugs by 2020
06/17 AMGEN : Appoints Esteban Santos Executive Vice President, Operations
06/17 AMGEN : Foundation Grant Funds Girl Scouts "Forever Green" Program
06/17 AMGEN : Appoints Esteban Santos Executive Vice President, Operations
06/14 AMGEN INC : Entry into a Material Definitive Agreement, Financial Statements and..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials